- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about REGN
Recent news which mentions REGN
What This Drug News Could Mean for Sanofi Shareholders
January 08, 2023
From Motley Fool
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
January 06, 2023
From InvestorPlace
CytomX Shares Move Higher On Collaborating Pact With This Famed COVID-19 Vaccine Maker
January 06, 2023
From Benzinga
3 Growth Stocks That Could Rocket Higher in 2023
January 06, 2023
From Motley Fool
Jim Cramer Says He's 'Still Feeling Good' About These 5 Stocks From 'Mutilated' Nasdaq
January 05, 2023
From Benzinga
2 Unstoppable Dividend Growth Stocks to Buy in 2023 and Beyond
December 29, 2022
From Motley Fool
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
From Benzinga
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
December 24, 2022
From Motley Fool
Ahead of a year of big unknowns, here are two sectors investors should consider, says this money manager
December 22, 2022
From MarketWatch
2 Best Biotech Stocks to Buy Right Now
December 16, 2022
From Motley Fool
Regeneron-Sanofi's Dupixent Wins European Approval For Prurigo Nodularis
December 15, 2022
From Benzinga
Regeneron Highlights Its First Phase 2 Data To Build Case In CD20xC3 Bispecific Space
December 12, 2022
Tickers
REGN
From Benzinga
Our 7 Top Biotech Stock Picks for 2023
December 09, 2022
From InvestorPlace
Will This Potential Approval Be a Winner for Sanofi's Shareholders?
December 09, 2022
From Motley Fool
This fund beats the S&P 500 by using just 75 of its components. Here’s how it works.
December 08, 2022
From MarketWatch
Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed
December 08, 2022
From Benzinga
Can These 2 Stocks Crush the Market Again in 2023?
December 04, 2022
From Motley Fool
Regeneron's Evkeeza Under FDA Priority Review For Younger Kids With Inherited Form Of High Cholesterol
November 30, 2022
Tickers
REGN
From Benzinga
UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent
November 30, 2022
From Benzinga
2 Market-Beating Stocks That Can Continue Rising in 2023
November 30, 2022
From Motley Fool
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
November 18, 2022
From Benzinga
CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron
November 17, 2022
From Benzinga
Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?
November 17, 2022
From InvestorPlace
Regeneron Pharmaceuticals's Return On Capital Employed Overview
November 17, 2022
Tickers
REGN
From Benzinga
2 Top Biotech Stocks to Buy in November
November 12, 2022
From Motley Fool
$100 Invested In This Stock 15 Years Ago Would Be Worth $4,000 Today
November 10, 2022
Tickers
REGN
From Benzinga
7 Cash-Rich Stocks to Buy for Peace of Mind
November 04, 2022
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.